CUROSURF
(Poractant alfa)ApprovedSmall molecule
Chiesi Farmaceutici S.p.A.CUROSURF is one of 104 small molecule programs targeting Hemorrhage. It is currently in Approved.
3
Indications
9
Total Trials
2
Active Trials
103
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncaspar
SServier
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Fludara
SanofiPhase 3
Medrol
PfizerPhase 3
Iclusig
TakedaPhase 3
Neoral
NovartisPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Arranon
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Respiratory Distress Syndrome3 trials
Perfusion Index Variability in Respiratory Distress Syndrome
Completed·—·N/A·NCT01852461·92 enrolled
Efficacy1 trial
Hemorrhage1 trial
Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage
Completed·—·N/A·NCT01860014·20 enrolled
Adult Acute Respiratory Distress Syndrome1 trial
2 more indications
Regulatory
FDA Approval Timeline[4]
Nov 18, 1999
CUROSURF
BLA BLA020744
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Poractant alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company